Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

…, TJ Walley, K Farrar, BK Park, AM Breckenridge - Bmj, 2004 - bmj.com
Objective To ascertain the current burden of adverse drug reactions (ADRs) through a prospective
analysis of all admissions to hospital. Design Prospective observational study. Setting …

Adverse drug reactions

M Pirmohamed, AM Breckenridge, NR Kitteringham… - Bmj, 1998 - bmj.com
Methods We conducted a search on the BIDS ISI database between 1981 and 1997 using
key words such as toxicity and hypersensitivity combined with drug. The references most …

Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

HG Eichler, E Abadie, A Breckenridge… - Nature reviews Drug …, 2011 - nature.com
Drug regulatory agencies should ensure that the benefits of drugs outweigh their risks, but
licensed medicines sometimes do not perform as expected in everyday clinical practice. …

Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo …

JJ Aponte, D Schellenberg, A Egan, A Breckenridge… - The Lancet, 2009 - thelancet.com
Background Intermittent preventive treatment (IPT) is a promising strategy for malaria
control in infants. We undertook a pooled analysis of the safety and efficacy of IPT in infants (IPTi) …

Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma

…, B Flamion, H Leufkens, A Breckenridge - Nature Reviews Drug …, 2008 - nature.com
Drug regulatory agencies are increasingly pressed by the challenge of finding the
appropriate balance between the need for rapid access to new drugs and the need to ensure …

Overcoming the legal and regulatory barriers to drug repurposing

A Breckenridge, R Jacob - Nature reviews Drug discovery, 2019 - nature.com
Drug repurposing has been proposed as a strategy to develop new therapies that has fewer
risks, lower costs and shorter timelines than developing completely new drugs. However, …

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

…, J Heavey, JF Tjia, SE Gibbons, AM Breckenridge… - Aids, 1997 - journals.lww.com
Objective: The most important hepatic enzyme involved in the metabolism of protease inhibitors
is cytochrome P450 3A4 (CYP3A4). Ritonavir (RIT) is a potent inhibitor of CYP3A4 and …

The risks of risk aversion in drug regulation

…, D Brasseur, A Breckenridge… - Nature reviews Drug …, 2013 - nature.com
Drugs are approved by regulatory agencies on the basis of their assessment of whether the
available evidence indicates that the benefits of the drug outweigh its risks. In recent years, …

[HTML][HTML] Open clinical trial data for all? A view from regulators

HG Eichler, E Abadie, A Breckenridge… - PLoS …, 2012 - journals.plos.org
Alasdair Breckenridge, … Alasdair Breckenridge, … Citation: Eichler HG, Abadie E,
Breckenridge A, Leufkens H, Rasi G (2012) Open Clinical Trial Data for All? A View from …

Clinical pharmacokinetics of anthelmintic drugs

G Edwards, AM Breckenridge - Clinical pharmacokinetics, 1988 - Springer
A rational strategy for chemotherapy demands that dosage schedules be based on an
adequate knowledge of clinical and biochemical pharmacology. Many anthelmintic drugs (eg …